Evidence map›Paper›PMID 38298257›Full record

ArticleFrontiers in public health2023

Ready for new waves: optimizing SARS-CoV-2 variants monitoring in pooled samples with droplet digital PCR.

Antonella Pacini, Franco Paredes, Sofia Heckel, Guadalupe Ibarra, Maria Victoria Petreli, Marilina Perez, Yanina Agnella, Laura Piskulic, Maria Belen Allasia, Luis Caprile and 2 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonella Pacini *Molecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Franco Paredes *Molecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Sofia HeckelMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Guadalupe IbarraMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Maria Victoria PetreliMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Marilina PerezMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Yanina AgnellaMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Laura PiskulicÁrea Estadística y Procesamiento de Datos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Maria Belen AllasiaÁrea Estadística y Procesamiento de Datos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Luis CaprileMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.
Alejandro ColaneriConsejo Nacional de Investigaciones Científicas y Técnicas, Rosario, Argentina.
Juliana SesmaMolecular Biology Department, Hospital Provincial de Rosario, Rosario, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The declaration of the end of the Public Health Emergency for COVID-19 on May 11th, 2023, has shifted the global focus led by WHO and CDC towards monitoring the evolution of SARS-CoV-2. Augmenting these international endeavors with local initiatives becomes crucial to not only track the emergence of new variants but also to understand their spread. We present a cost-effective digital PCR-based pooled sample testing methodology tailored for early variant surveillance. Methods: Using 1200 retrospective SARS-CoV-2 positive samples, either negative or positive for Delta or Omicron, we assessed the sensitivity and specificity of our detection strategy employing commercial TaqMan variant probes in a 1:9 ratio of variant-positive to variant-negative samples. Results: The study achieved 100% sensitivity and 99% specificity in 10-sample pools, with an Area Under the Curve (AUC) exceeding 0.998 in ROC curves, using distinct commercial TaqMan variant probes. Discussion: The employment of two separate TaqMan probes for both Delta and Omicron establishes dual validation routes, emphasizing the method's robustness. Although we used known samples to model realistic emergence scenarios of the Delta and Omicron variants, our main objective is to demonstrate the versatility of this strategy to identify future variant appearances. The utilization of two divergent variants and distinct probes for each confirms the method's independence from specific variants and probes. This flexibility ensures it can be tailored to recognize any subsequent variant emergence, given the availability of its sequence and a specific probe. Consequently, our approach stands as a robust tool for tracking and managing any new variant outbreak, reinforcing our global readiness against possible future SARS-CoV-2 waves.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansPolymerase Chain ReactionRetrospective StudiesCOVID-19 pandemicDelta/Omicron trackingdroplet digital PCRnew variant outbreakPool testingSARS-CoV-2 wave surveillance

Identifiers

PMID38298257
PMCPMC10829044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.